lschemic tolerance is the genome's own endogenous protective response to ischemic stress. The goal of this application is to discover the genes and gene pathways regulating this protection and to do so with a goal of providing new therapeutic strategies for stroke. We will be guided by genes discovered in tolerance models developed in project 1 and genes further characterized as neuroprotective in vitro in project 2. We will then directly test Candidate gene products and candidate neuroprotective pathways in mice by use of routine models over-expressing a candidate gene, in knockouts or by altering the expression of the gene product of interest. We will use mouse lines available to us or create new models if required as we have done previously. Thus we plan to: 1) Determine whether increased expression or presence of candidate neuroprotective genes identified in Projects 1 and 2 using in vitro and in vivo models of preconditioning, improves neuronal survival in ischemia in vivo. 2) Determine whether decreased expression or inhibition of function of candidate neuroprotective genes, identified in Projects 1 and 2 using in vitro and in vivo models of preconditioning, reduces tolerance and neuronal survival in ischemia in vivo. 3) Determine which genes are altered in tolerance in the absence of neuroprotective genes to elucidate the function of novel genes in ischemic preconditioning. We will begin with a novel inflammatory pathway surrounding the osteopontin gene, which was revealed in our initial microarray screening. By a combined analysis of genes discovered in multiple models in vivo and in vitro in projects 1 and 2 our goal is to discover gene sets which share common promoter elements and reveal the common restricted pathways regulating tolerance to ischemia in brain. Knowledge of such pathways should be broadly relevant to injury states across organs and beyond ischemia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS035965-07
Application #
7553620
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2004-05-01
Budget End
2005-04-30
Support Year
7
Fiscal Year
2004
Total Cost
$340,122
Indirect Cost
Name
Emanuel Hospital and Health Center
Department
Type
DUNS #
050973098
City
Portland
State
OR
Country
United States
Zip Code
97232
Simon, Roger P (2016) Epigenetic modulation of gene expression governs the brain's response to injury. Neurosci Lett 625:16-9
Simon, Roger P; Meller, Robert; Zhou, An et al. (2012) Can genes modify stroke outcome and by what mechanisms? Stroke 43:286-91
Stevens, Susan L; Leung, Philberta Y; Vartanian, Keri B et al. (2011) Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci 31:8456-63
Stapels, Martha; Piper, Chelsea; Yang, Tao et al. (2010) Polycomb group proteins as epigenetic mediators of neuroprotection in ischemic tolerance. Sci Signal 3:ra15
Marsh, B J; Williams-Karnesky, R L; Stenzel-Poore, M P (2009) Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 158:1007-20
West, G Alexander; Golshani, Kiarash J; Doyle, Kristian P et al. (2009) A new model of cortical stroke in the rhesus macaque. J Cereb Blood Flow Metab 29:1175-86
Stevens, Susan L; Ciesielski, Thomas M P; Marsh, Brenda J et al. (2008) Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 28:1040-7
Doyle, Kristian P; Yang, Tao; Lessov, Nikola S et al. (2008) Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab 28:1235-48
Khan, Adil A; Mao, Xiao Ou; Banwait, Surita et al. (2008) Regulation of hypoxic neuronal death signaling by neuroglobin. FASEB J 22:1737-47
Pignataro, Giuseppe; Maysami, Samaneh; Studer, Francesca E et al. (2008) Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. J Cereb Blood Flow Metab 28:17-23

Showing the most recent 10 out of 74 publications